E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Prevention of disease caused by a type of bacteria called Streptococcus pneumoniae (pneumococcal disease). |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To describe the safety and immunogenicity profile of 20vPnC |
|
E.2.2 | Secondary objectives of the trial |
To further describe the immune responses to 20vPnC |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Male or female children ≥15 months to <18 years of age at the time of consent. - Healthy children determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study. - For children <5 years of age, written documentation of receipt of at least 3 doses of 13vPnC. The last dose of 13vPnC must have been administered >2 months before enrolment into the study |
|
E.4 | Principal exclusion criteria |
- History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) - Major known congenital malformation or serious chronic disorder - Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results - Previous vaccination with any investigational pneumococcal vaccine or with PPSV23, or planned receipt through study participation - Cohorts 3 and 4: Pregnant or breastfeeding female participants |
|
E.5 End points |
E.5.1 | Primary end point(s) |
- The percentage of participants reporting prompted local reactions within 7 days after vaccination - The percentage of participants reporting prompted systemic events within 7 days after vaccination - The percentage of participants reporting Adverse Events (AEs) up to 1 month after vaccination - The percentage of participants reporting Serious Adverse Events (SAEs) up to 6 months after vaccination - The percentage of participants reporting Newly Diagnosed Chronic Medical Conditions (NDCMCs) up to 6 months after vaccination - Immunoglobulin G (IgG) Geometric Mean Fold Rises (GMFRs) for the 7 additional serotypes 1 month after vaccination - Opsonophagocytic activity (OPA) GMFRs for the 7 additional serotypes 1 month after vaccination |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
- Day 7 - Day 7 - 1 month after vaccination - 6 months after vaccination - 6 months after vaccination - 1 month after vaccination - 1 month after vaccination |
|
E.5.2 | Secondary end point(s) |
- Percentage of participants with predefined serotype-specific IgG concentrations for the 7 additional serotypes at 1 month after vaccination in Cohort 1 only - Percentage of participants with ≥4-fold rise in serotype-specific OPA titers for the 7 additional serotypes from before to 1 month after vaccination in Cohorts 2, 3, and 4 only - IgG Geometric Mean Concentrations (GMCs) for the 20vPnC serotypes before and 1 month after vaccination - IgG GMFRs for the 13vPnC serotypes from before to 1 month after vaccination - IgG GMFRs for the 20vPnC serotypes from before to 1 month after vaccination - OPA Geometric Mean Titers (GMTs) for the 20vPnC serotypes before and 1 month after vaccination - OPA GMFRs for the 20vPnC serotypes from before to 1 month after vaccination - OPA GMFRs for the 13vPnC serotypes from before to 1 month after vaccination |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- 1 month after vaccination - from before to 1 month after vaccination - before and 1 month after vaccination - before to 1 month after vaccination - before to 1 month after vaccination - before and 1 month after vaccination - before to 1 month after vaccination - before to 1 month after vaccination
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 2 |